Related Experiment Video
Updated: Jul 19, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Pioglitazone for type 2 diabetes mellitus
B Richter1, E Bandeira-Echtler, K Bergerhoff
1Universitaetsklinikum Duesseldorf, Department of Endocrinology, Diabetes and Rheumatology, Moorenstr. 5, Duesseldorf, Germany. richterb@uni-duesseldorf.de
The Cochrane Database of Systematic Reviews
|October 21, 2006
Summary
Pioglitazone treatment for type 2 diabetes shows no clear benefit for patient outcomes like mortality or quality of life. Further research is needed to clarify its overall benefit-risk ratio for diabetes management.
Area of Science:
- Endocrinology
- Pharmacology
- Cardiovascular Medicine
Background:
- Diabetes is a major risk factor for cardiovascular disease, accounting for a significant portion of mortality in affected individuals.
- Previous large trials in type 2 diabetes did not demonstrate improved cardiovascular outcomes with metabolic control.
- Peroxisome proliferator activated receptor gamma (PPAR-gamma) activators, such as pioglitazone, have theoretical benefits for endothelial function and cardiovascular risk factors.
Purpose of the Study:
- To evaluate the efficacy and safety of pioglitazone in treating type 2 diabetes mellitus.
- To assess the impact of pioglitazone on patient-oriented outcomes and surrogate endpoints.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs) of pioglitazone in adults with type 2 diabetes.
- Studies included had a minimum duration of 24 weeks.
- Data on adverse events were pooled using random-effects meta-analysis.
Main Results:
- Twenty-two trials involving approximately 6200 patients were analyzed.
- Pioglitazone treatment (≥24 weeks) did not provide convincing evidence of positive influence on mortality, morbidity, or quality of life.
- While HbA1c levels showed no clinically relevant differences compared to other oral antidiabetics, edema occurrence was significantly increased.
Conclusions:
- The benefit-risk ratio of pioglitazone remains uncertain pending new evidence.
- Clarification of differing therapeutic indications by regulatory agencies is needed to reduce patient and physician uncertainty.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...